Skip to main content

Table 2 Characteristics of all trials. Majority of trials treated patients with 3D conventional techniques, had a sample size of 200 or more, were not industry sponsored, were listed in clinicaltrials.gov, were RT focused, had non-overall survival as the primary efficacy endpoint and were published in Europe. There were more trials published in radiotherapy journals, published form 1996-2005, published in journals with impact factor of more then 15. Majority of trials were non-cooperative group trials, did not publish their trial protocol, did not publish their QA processes, and did not have biases in reporting of primary efficacy endpoints and toxicity

From: Quality of radiotherapy reporting in randomized controlled trials of prostate cancer

Characteristics N %
RT Technique
 2D 1 2
 3D Conventional 33 56
 IMRT only 5 8
 Multiple techniques 11 19
 Not specified 9 15
Sample size
  ≤ 200 16 27
  > 200 43 73
Sponsorship
 Industry 12 20
 Not industry 33 56
 Not reported 14 24
Listed in clinicaltrials.gov
 Yes 15 25
 No 44 75
Types of RT trial
 RT focused 40 68
 Not RT focused 19 32
Primary efficacy endpoint
 Overall survival 8 14
 Non-overall survival 42 86
Region
 North America 21 36
 Europe 31 52
 Asia 3 5
 Australia/New Zealand 3 5
 International 1 2
Radiotherapy Journal
 Yes 17 29
 No 42 71
Year of publication
 1996–2005 36 61
 2006–2016 23 39
Impact factor
  ≤ 15 18 31
  > 15 41 69
Cooperative group
 Yes 23 39
 No 36 61
Trial protocol available
 Yes 14 24
 No 45 76
QA process published
 Yes 16 27
 No 43 83
Bias in reporting primary efficacy endpoint
 Yes 4 7
 No 44 75
 Not accessible 11 18
Bias in reporting toxicity
 Yes 13 22
 No 46 78